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Background: With drug-related deaths at record levels in the UK, the government faces two potential sources 
of pressure to implement more effective policies. One source is the individuals and families who are most 
likely to suffer from such deaths; i.e. working class people living in de-industrialised areas. The other source is 
experts who argue for different policy on the basis of research evidences.  
Aim: This article aims to explain why, in the face of these two potential sources of pressure, the UK 
government has not implemented effective measures to reduce deaths. 
Method: The article uses critical realist discourse analysis of official documents and ministerial speeches on 
recent British drug policy (2016-2018). It explore this ĚŝƐĐŽƵƌƐĞƚŚƌŽƵŐŚƚŚĞƚŚĞŽƌĞƚŝĐĂůůĞŶƐŽĨƌĐŚĞƌ ?Ɛ (2000) 
ŝĚĞĂƐŽŶ ‘ďĞŝŶŐŚƵŵĂŶ ?ĂŶĚďǇĚƌĂǁŝŶŐŽŶ^ĂǇĞƌ ?Ɛ ? ? ? ? ? ?work ŽŶƚŚĞ ‘ŵŽƌĂůƐŝŐŶŝĨŝĐĂŶĐĞŽĨĐůĂƐƐ ? ?
Results: DĞŵďĞƌƐŽĨĞĐŽŶŽŵŝĐĂůůǇ ‘ƌĞƐŝĚƵĂů ?ŐƌŽƵƉƐ ?including working class people who use heroin) are 
ĞǆĐůƵĚĞĚĨƌŽŵĂƌƚŝĐƵůĂƚŝŶŐƚŚĞŝƌŝŶƚĞƌĞƐƚƐŝŶ ‘ůĂƚĞǁĞůĨĂƌĞĐĂƉŝƚĂůŝƐŵ ?ŝŶĂƉƌŽũĞĐƚŽĨdepersonalising  ‘ĐůĂƐƐ
ĐŽŶƚĞŵƉƚ ?ƚŚƌŽƵŐŚǁŚŝĐŚƉŽůŝƚŝĐŝĂŶƐĐĂƐƚƚŚĞƉĞŽƉůĞŵŽƐƚůŝŬĞůǇƚŽĚŝĞĂƐƉĂƐƐŝǀĞ ? ‘ǀƵůŶĞƌĂďůĞ ?  ‘ĂďũĞĐƚƐ ? ?
Conservative politicians dismiss  ‘ĞǀŝĚĞŶĐĞ-ďĂƐĞĚ ? ideas on the reduction of drug-related death through a 
 ‘ŵŽƌĂůƐŝĚĞƐƚĞƉ ? ?They defend policy on the basis of its relevance to conservative moral principles, not 
effectiveness. This is consistent with the broader moral and political pursuit of partial state shrinkage which 
Conservative politicians and the social groups they represent have pursued since the 1970s. 
 
Keywords: critical realist discourse analysis; drug-related death; evidence-based policy; class contempt; 





This article aims to explain why, having received clear advice on how to reduce record levels of drug-
related deaths, the UK government has done so little to implement effective, life-saving measures. 
The UK government faces pressure to change policy from two potential sources; the individuals and 
families who are most likely to suffer from drug-related deaths; and experts who know the research 
on what measures have shown to be effective in reducing deaths and who wish to see this 
ƚƌĂŶƐůĂƚĞĚŝŶƚŽ ‘ĞǀŝĚĞŶĐĞ-ďĂƐĞĚƉŽůŝĐǇ ? ? dŽƵŶĚĞƌƐƚĂŶĚƚŚĞŐŽǀĞƌŶŵĞŶƚ ?ƐĨĂŝůƵƌĞƚŽrecognise or 
respond to these pressures requires some understanding of ƚŚĞh< ?Ɛ political economy. 
 
Many of the people who are currently dying came of age under the Conservative government of 
1979 to 1997. Its political ideology still inform current policies. Margaret Thatcher was inspired by 
her intellectual mentors - Friedrich Hayek and Milton Friedman, as interpreted by Keith Joseph 
(Harrison, 1994). Through her, Joseph bequeathed some durable beliefs to the generation of 
Conservative politicians who also came to political maturity under her influence. This includes the 
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 ‘ĨĂĐƚ ?ƚŚĂƚ ‘ƚŚĞƌĞĂƌĞƐĐƌŽƵŶŐĞƌƐ ?ƵŶĞŵƉůŽǇĂďůĞƐĂŶĚƉĞople who will not make their share of the 
effort' (Joseph, 1976, p. 15). For Joseph, and for many Conservative politicians since, the principles 
of freedom, justice and economic efficiency demand that people have to be freed from dependence 
on the state, which has to be shrunk. The partiality of this project of state shrinkage has since been 
demonstrated by the policies used in the aftermath of the 2007/8 financial crisis. Money was 
simultaneously handed to financial institutions and shareholders through quantitative easing, and 
taken away from people living in poverty by cutting social security in an intensified programme of 
 ‘ǁĞůĨĂƌĞƌĞĨŽƌŵ ?(Grimshaw & Rubery, 2012; Sharpe & Watts, 2013; Taylor-Gooby, 2016). 
 
The initial implementation of dŚĂƚĐŚĞƌ ?Ɛ policies created mass unemployment in south Wales, the 
north of England and the central belt of Scotland. People who had  ‘ŶŽǁƚĞůƐĞ ? ?WĞĂƌƐŽŶ ? ? ? ? ? ?
turned to heroin. Many of these people have continued to use heroin and other substances, 
including tobacco and alcohol, over many years. It is they who are now most at risk of drug-related 
deaths. These deaths are concentrated in people over 40, who live in these deindustrialised areas 
(NRS, 2017; ONS, 2017). Rates of recorded  ‘drug misuse ? deaths are nine times higher in the most 
deprived decile of neighbourhoods in England than they are in the least deprived decile (117.5 
compared to 13.5 per million population, ONS, 2018). In the UK, drug-related deaths primarily affect 
working class people.  
 
As we will see, these people have a marginal presence in British drug policy making, while 
professional experts have long been central to it (Berridge, 2013). This is the second group with 
potential influence in changing drug policy to reduce deaths. They have succeeded in doing so in the 
past. A particularly influential role has been played by the Advisory Council on the Misuse of Drugs 
(ACMD). This was established by the Misuse of Drugs Act 1971 to provide independent advice to 
ministers on the reduction of drug-related harms (MacGregor, 2017).  In response to its report on 
HIV/AIDS (ACMD, 1988), the Thatcher government supported a range of harm reduction approaches 
that limited the spread of HIV among people who were injecting drugs (Hope et al., 2005; 
MacGregor, 1998, 2017; Stimson, 1996).  
 
The ACMD (2000) then recommended a number of measures that would reduce deaths. Some (but 
not all) of these were implemented, including a rapid expansion in the delivery of opioid substitution 
therapy (OST). Deaths subsequently fell. But they have risen dramatically since 2012 (ONS, 2017). In 
response, the ACMD reported to ministers on how to reduce opioid-related deaths, which still make 
up the largest share of deaths that are recorded as being related to drug misuse. I was the co-chair 
of the ACMD sub-committee that wrote this report (ACMD, 2016a)1.  
 
Our main recommendations were: to improve the reporting and recording of drug-related deaths; to 
invest in OST of optimal dosage and duration; to expand the provision of naloxone for the reversal of 
opioid overdose; to provide central funding of heroin-assisted treatment (HAT) for people for whom 
other forms of OST are not effective; to consider the establishment of medically supervised drug 
consumption rooms (DCRs) in areas with high concentrations of injecting drug use; to support 
integrated treatment for people with complex needs; and to invest more in relevant research to fill 
                                                          
1 The views in this article do not represent those of the ACMD as a whole. In writing it, I have not used any 
information that is available to members of the ACMD but not the public. 
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important knowledge gaps. We also repeated earlier recommendations (ACMD, 1998, 2000) to take 
steps to address the socio-economic deprivation which is conducive to the development of 
problematic drug use.  
 
As shown below, there has been minimal implementation ŽĨƚŚĞƌĞƉŽƌƚ ?ƐƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐ, 
especially in England; the only country in which the UK government has direct responsibility for all 
aspects of drug policy (health policy is devolved to the national governments of Scotland, Wales and 
Northern Ireland). So the UK government faces a serious social problem which primarily affects an 
identifiable social group (middle-aged, working class people, living in de-industrialised areas). It has 
received advice from the body which is officially responsible for providing it, and which has told it 
that failure to follow the advice will predictably lead to avoidable deaths (ACMD, 2016a). But it has 
not implemented such measures. How do we explain this failure to use  ‘ĞǀŝĚĞŶĐĞ-ďĂƐĞĚ ?
interventions to save the lives of UK citizens?  
 
In answering this question, I present a critical realist explanation that follows Margaret ƌĐŚĞƌ ?s 
ideas on the interplay between agency, culture and structure in the creation of social practices, as 
presented in her 2000 book, Being Human. It also uses ŶĚƌĞǁ^ĂǇĞƌ ?Ɛ ? ? ? ? ? ?ŝŶƐŝŐŚƚƐŽŶThe Moral 
Significance of Class. I apply these concepts in analysing data from political discourse on drug-related 
ĚĞĂƚŚƐ ?/ƐŚŽǁƚŚĂƚƉĂƌƚŽĨƚŚĞĞǆƉůĂŶĂƚŝŽŶŵƵƐƚďĞƚŚĂƚƚŚĂƚƚŚĞƉĞŽƉůĞǁŚŽŚĂǀĞƚŚĞ ‘ĐŽƌƉŽƌĂƚĞ
ĂŐĞŶĐǇ ?ƚŽĚĞĐŝĚĞƚŚĞĐŽŶƚĞŶƚŽĨĚƌƵŐƉŽůŝĐǇŚĂǀĞƵƐĞĚƚŚĞŝƌƉŽǁĞƌƚŽŝŶƐƚŝƚƵƚŝŽŶĂůŝƐĞĚŝƐĐŽƵƌƐĞƐ
which deny fully human status to the people who suffer most from opioid-related deaths. According 
to Archer (2000), corporate agency is a quality of a collectivity that has recognised its common 
interest and is able to act strategically towards shared goals. In this case, the corporate agent is the 
social collectivity whose interests are represented by the Conservative Party, including the financial 
services industry which provides much of its funding (Channel 4 News, 2017), and many of its most 
prominent members, including Prime Minister Theresa May and then Home Secretary Amber Rudd 
(both former bankers). These powerful actors meet demands for the use of evidence to save lives 
ǁŝƚŚĂ ‘ŵŽƌĂůƐŝĚĞƐƚĞƉ ?ƚŽǁĂƌĚƐŶŽƌŵĂtive positions that rest on tough enforcement of conformity 
and purity rather than  ‘liberal ? compassion. 
 
Method and data  
 
The method I use here is critical realist discourse analysis (Flatschart, 2016; Sims-Schouten, Riley, & 
Willig, 2007). This starts by identifying the extra-discursive features to which discourses in the field 
of study may relate. It proceeds by analysing the ways in which these features are represented in the 
texts and utterances of participants in that field. Here, I examine the way some possible 
representations of the field are articulated and how some others are  ‘ƐŝůĞŶƚůǇsilenced ? (Mathiesen, 
2004). 
 
The texts and speeches for analysis were chosen on the basis of their relevance to the question of 
how we can explain the non-implementation of effective measures to reduce opioid-related deaths. 
I therefore chose to include official documents and ministerial speeches that were made on the 
subject from the publication of the ACMD report in December 2016 until the start of this analysis 
(February 2018). The official documents include the govĞƌŶŵĞŶƚ ?ƐĞǀĂůƵĂƚŝŽŶŽĨƚŚĞ ? ? ? ?ĚƌƵŐ
strategy (HM Government, 2017a). This was stated to have informed the development of the new 
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drug strategy, which was also published in July 2017 (HM Government, 2017b). Alongside these two 
documents, the government published its response to the ACMD (2016a) report (Brine & Newton, 
2017). On the eve of the publication of the drug strategy, the Home Secretary also published a blog 
on the Huffington Post website (Rudd, 2017). This is also included in the analysis.  
 
In order to gather ministerial speeches, I used the Hansard website. Hansard is the official record of 
British parliamentary proceedings. I searched for speeches and answers to questions on subjects 
related to drug-related deaths that were given by government ministers in the House of Commons in 
the chosen period. This produced a dataset of 30 debates and answers to oral and written questions.  
 
I analysed these texts using Nvivo software. First, I developed a list of provisional codes (Layder, 
1998) from my reading of Archer (2000), Sayer (2005) and from my own experience in the field. I 
then systematically read and re-read the texts, assigning sections of text to these codes, and creating 
other codes when I noticed new aspects in the data  ?ƚŚŝƐŝŶĐůƵĚĞƐƚŚĞ ‘ŵŽƌĂůƐŝĚĞƐƚĞƉ ?ĚĞƐĐƌŝďĞĚ
below).  I then re-read the coded extracts of texts and organised them into the three sections 
presented below. My aim in doing so was to reconstruct the arguments that government officials 
and politicians deployed in these texts; the reasons they gave for acting as they did and the ways in 
which the texts blocked off or ignore other forms of action. In this way, this was a form of 
 ‘argumentative analysis ? (Thompson, 1990). 
 
Extra-discursive features of the field 
 
My selection of extra-discursive features that are relevant to the analysis was informed by three 
strands of activity: long-term participant observation in and study of the British drug policy scene 
(Hunt & Stevens, 2004; Stevens, 2011a, 2017); my experience of the process of initiating, writing, 
negotiating and disseminating the ACMD (2016a) report on opioid-related deaths; and the review of 
the research evidence on how to explain and reduce these deaths that I led in producing this ACMD 
report.  
 
These extra-discursive features include: the rise in opioid-related deaths (ONS, 2017); the 
distribution of these deaths by geography and neighbourhood deprivation (ONS, 2018); the 
government ?ƐƌĞĚƵĐƚŝŽŶŽĨthe share of national income that is devoted to public spending (Taylor-
Gooby, 2016); substantial cuts to central funding of local authorities, which have been concentrated 
on the most deprived areas (Hastings, Bailey, Bramley, Gannon, & Watkins, 2015); the use of fiscal 
policy to redistribute income from poor to rich groups in the UK (Emmerson, 2018); and the related 
process of welfare reform. In its reforms to the social security system, the UK government has 
shifted responsibility ƚŽƉŽŽƌƉĞŽƉůĞƚŽƉƌŽǀĞƚŚĂƚƚŚĞǇĂƌĞŶŽƚ ‘ǁĞůĨĂƌĞƐĐƌŽƵŶŐĞƌƐ ?(Wincup & 
Monaghan, 2016), echoing JŽƐĞƉŚ ?Ɛ ? ? ? ? ? ?ŝĚĞŶƚŝĨŝĐĂƚŝŽŶŽĨƚŚĞ ‘ƵŶĞŵƉůŽǇĂďůĞ ? ‘ƐĐƌŽƵŶŐĞƌ ? as a 
policy target. Discursively, this stereotype has been supported by the propagation of unfounded 
myths, such as the widespread existence of families in which several generations have never worked 
and of neighbourhoods where nobody works (Macdonald, Shildrick, & Furlong, 2014).  
 
Since their party entered government in 2010, Conservative ministers have frequently used this 
ŝŵĂŐŝŶĂƌǇ ‘ĐƵůƚƵƌĞŽĨǁŽƌŬůĞƐƐŶĞƐƐ ?ƚŽũƵƐƚŝĨǇƌĞƚƌĞŶĐŚŵĞŶƚŝŶǁĞůĨĂƌe spending. The real effects of 
this discourse have included introduction of a punitive sanctions regime for people who do not 
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comply with increased conditionality in welfare benefits, abolition of two benefits that were relied 
on by many people with drug problems (incapacity benefit and disability living allowance), and the 
ƌŽůůŝŶŐŽĨƚĂǆĐƌĞĚŝƚƐĂŶĚďĞŶĞĨŝƚƐŝŶƚŽŽŶĞ ?ůĞƐƐŐĞŶĞƌŽƵƐĂŶĚĨĂŝůŝŶŐƐǇƐƚĞŵŽĨ ‘hŶŝǀĞƌƐĂůƌĞĚŝƚ ?
(NAO, 2018). Social marginalisation has been intensified as poor people  W and especially those with 
drug problems - have been rendered increasingly responsible for solving the problem of poverty 
through their own efforts (Patrick, 2012; Roy & Buchanan, 2016; Wiggan, 2012). 
 
These latest developments relate to another extra-discursive feature that shapes policy agendas and 
responses in the UK. Its society and politics have long been structured by social class (Parkin, 1972; 
Thompson, 1963). Class may no longer be as easy to discern as it once was; it is now comprises of 
 ‘ŵƵůƚŝƉůĞĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶƐ ?(Sayer, 2005, p. 15). But it continues to influence aspirations, expectations, 
tastes, life expectancy and prospects, incomes, wealth, consumption patterns, voting intentions, and 
affective relationships (Dorling, 2014; Savage, 2000; Savage et al., 2013; Skeggs, 2004; Skeggs & 
Loveday, 2012). Members of different social classes also tend to hold different attitudes towards the 
suffering of materially poor people. Social surveys and qualitative interviews suggest that people in 
the higher income groups are more likely to see poverty as an individual failing and to resist policies 
which redistribute resources to the poor (Edmiston, 2017; Kantola & Kuusela, 2018; Lamont, 1992; 
Svallsfors, 2006) ?WƐǇĐŚŽůŽŐŝĐĂůĞǆƉĞƌŝŵĞŶƚƐƚĞůůƵƐƚŚĂƚ ‘ ?ŝ ?ŶĚŝǀŝĚƵĂůƐŽĨ ower social class display 
ŝŶĐƌĞĂƐĞĚĂƚƚĞŶƚŝŽŶƚŽŽƚŚĞƌƐĂŶĚŐƌĞĂƚĞƌƐĞŶƐŝƚŝǀŝƚǇƚŽŽƚŚĞƌƐ ?ǁĞůĨĂƌĞĐŽŵƉĂƌĞĚƚŽŝŶĚŝǀŝĚƵĂůƐŽĨ
higher social class, who exhibit more self-ŽƌŝĞŶƚĞĚƉĂƚƚĞƌŶƐŽĨƐŽĐŝĂůĐŽŐŶŝƚŝŽŶ ?(Piff & Robinson, 
2017, p. 6). People tend to be more inclined to show compassion to people whom they consider to 
be socially similar (Sayer, 2005). Sayer argues that such evaluations are made on the basis of moral 
judgements along lines of class.  The failure by one social class to recognise and act on the needs of 
ĂŶŽƚŚĞƌŝƐĂĨŽƌŵŽĨ ‘ĐůĂƐƐĐŽŶƚĞŵƉƚ ? ?Žƌ ‘ƚŚĞƚĞŶĚĞŶĐǇŶŽƚƚŽƐĞĞŽƌŚĞĂƌŽƚŚĞƌƐĂƐƉĞŽƉůĞ ?(Sayer, 
2005, p. 163) on the basis of their class position. 
 
 
Data and discourse analysis 
 
The non-performative absorption of recommendations  
 
In their response to the ACMD (2016a) report, the relevant junior ministers from the Home Office 
and the Department of Health and Social Care declared that they  ‘accepted the majority of the 
ƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐŝŶƚŚĞƌĞƉŽƌƚ ? with the exception of drug consumption ƌŽŽŵƐ ?(Brine & Newton, 
2017). In the usual meaning of the words, to accept a recommendation implies that you agree with it 
and will implement it. However, analysis of this ministerial response and subsequent speeches and 
actions shows that ministers do not agree with the recommendations and do not intend to 
implement them.  
 
The response to the recommendations welcomed ƚŚĞD ?ƐĂĚvice, but treated it selectively. It 
referred to actions that the government was already taking (of which ACMD members were already 
aware), instead of accepting the need for new action. The letter which the chair of the ACMD had 
sent to Amber Rudd with the report emphasised  ‘[t]he most important recommendation in this 
report is that government ensures that investment in OST of optimal dosage and duration is, at least, 
maintained ? ?dŚĞŵŝŶŝƐƚĞƌŝĂůƌĞƐƉŽŶƐĞ ?ĂŶĚŽƚŚĞƌƚĞǆƚƐŝŶƚŚĞĚĂƚĂƐĞƚ ?ƐĂǇƐŶŽƚŚŝŶŐĂďŽƵƚĚŽƐĂŐĞŽƌ
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duration of OST, other than to refer to national clinical guidelines. As the ACMD and others have 
suggested, these guidelines have not been sufficient to achieve optimal dosage and duration of OST 
in practice (ACMD, 2014, 2015; Hickman et al., 2018; Recovery Orientated Drug Treatment Expert 
Group, 2012), which is why new governmental action was recommended.  
 
The ACMD (2016a) ƌĞƉŽƌƚĂŶĚƚŚĞŐŽǀĞƌŶŵĞŶƚ ?ƐŽǁŶĞǀĂůƵĂƚŝŽŶŽĨƚŚĞ ? ? ? ?ĚƌƵŐƐƚƌĂƚĞŐǇ(HM 
Government, 2017a) show reductions in spending on treatment, including OST. Accepting the ACMD 
recommendations in this area would involve acknowledging that more spending is necessary, 
relative to ongoing reductions. Instead, the ministerial response claimed that spending was being 
ŵĂŝŶƚĂŝŶĞĚƚŚƌŽƵŐŚƚŚĞƌĞƚĞŶƚŝŽŶŽĨƚŚĞ ‘ƌŝŶŐ-ĨĞŶĐĞĚŐƌĂŶƚ ?ƵŶƚŝů ? ? ? ? ? ? ? ?ĂĚŝƐƐŝŵƵůĂƚŝŽŶŽĨƚŚĞĨĂĐƚ
that substantial cuts to both the central public health grant and to funding for local authorities have 
created a serious threat to treatment coverage and quality (ACMD Recovery Committee, 2017). 
 
The ministerial response also included acceptance of recommendations on HAT and naloxone. The 
ACMD (2016a ?ƐƉĞĐŝĨŝĐĂůůǇƌĞĐŽŵŵĞŶĚĞĚ ‘ĐĞŶƚƌĂůĨƵŶĚŝŶŐ ?ŽĨ,d ?ĚƵĞƚŽƚŚĞĨĂŝůƵƌĞŽĨůŽĐĂůĨƵŶĚŝŶŐ
to sustain the three clinics that had been providing the service until 2015. The ministerial response 
belied its pretended agreement with the ACMD by arguing that such services should be funded 
locally. No new central funding for HAT has been provided.  
 
On naloxone, the ministerial response and the 2017 drug strategy refer to a range of existing efforts 
(but no new funding) to encourage local agencies to provide naloxone. As an analysis by the charity 
Release has shown, these initiatives have so far failed to provide anything more than patchy and 
inadequate provision of naloxone in England (Release, 2017). Most worryingly, some local 
authorities with relatively high levels of drug-related deaths (e.g. Wigan and Hartlepool) reported to 
Release that they had no plans to make take-home naloxone available.  
 
Another example of the lack of agreement and implementation of these  ‘ĂĐĐĞƉƚĞĚ ?
recommendations is the approach taken to research funding. The ACMD (2016a) reported important 
gaps in knowledge. Its response to an earlier draft of the drug strategy had also highlighted 
substantial evidence gaps, particularly in the areas of demand and supply reduction (ACMD, 
2016b).This was backed up by ƚŚĞŐŽǀĞƌŶŵĞŶƚ ?ƐĚƌƵŐƐƚƌategy evaluation, which noted a lack of 
evidence on several aspects of UK drug policy (HM Government, 2017a). The ACMD (2016a) report 
suggested seven specific areas of necessary research, six of which go beyond the evaluation of 
health interventions to reduce deaths.  The ministerial response and other texts (including the 2017 
drug strategy) did not acknowledge these evidence gaps and did not create new research projects or 
investment. In the government debate that introduced the new drug strategy, the minister rather 
said  ‘ǁĞŚĂǀĞĂŐŽŽĚĞǀŝĚĞŶĐĞďĂƐĞƵƉŽŶǁŚŝĐŚƚŽďƵŝůĚĨŽƌƚŚĞĨƵƚƵƌĞ ?(Newton, 2017). 
 
The ministerial response to the ACMD referred to existing funding of research through the National 
Institute of Health Research (NIHR), the collation of law-enforcement data by the National Crime 
Agency (NCA), ĂŶĚƚŚĞh< ?ƐƉĂƌƚŝĐŝƉĂƚŝŽŶin the European Research Area Network on Illicit Drugs 
(ERANID). NIHR is not a specific funder of drug-related research. It has not been able to meet the 
need for research in this field since it was created in 2006, probably due to the very large range of 
other topics that it covers. In the most recent publicly available data on spending on health research 
(UK Clinical Research Collaboration, 2015), less than one percent of approximately £2 billion in 
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reported funding was devoted to issues of drug  ‘addiction ? or opiate use. All of the funded projects 
on these topics focus on prevention or treatment of drug use. This is far from meeting the range of 
evidence gaps identified by the ACMD and the drug strategy evaluation. For example, it does nothing 
to inform us on the effectiveness of investment in supply reduction and law enforcement.  
 
These gaps cannot be met through data gathered by the NCA. The NCA is not a research 
organisation. It publishes very little of the data it collects. The government does participate in the 
ERANID research initiative. But the ministerial response failed to mention that the UK opted out of 
the ERANID (2016) call ĨŽƌƌĞƐĞĂƌĐŚŽŶ ‘ƚŚĞŝŵƉĂĐƚŽĨĚƌƵŐƉŽůŝĐǇ ŽŶƐŽĐŝĞƚǇ ?, so limiting the ability of 
British researchers to produce evidence on drug demand and supply reduction. 
 
dŚĞŐŽǀĞƌŶŵĞŶƚ ?ƐƐƚĂƚĞĚĂĐĐĞƉƚĂŶĐĞŽĨƚŚĞDƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐĂƌĞĂŶĞǆĂŵƉůĞŽĨ ‘non-
performative language ? ?/ƚŝƐĂƐĞƚŽĨƐƚĂƚĞŵĞŶƚƐƚŚĂƚ ‘ĚŽŶŽƚďƌŝŶŐĂďŽƵƚƚŚĞĞĨĨĞĐƚƐƚŚĂƚƚŚĞǇŶĂŵĞ ?
(Ahmed, 2006) ?/ŶDĂƚŚŝĞƐĞŶ ?Ɛ(2004) terms, this non-performative acceptance of recommendations 
ƐĞƌǀĞƐƚŽ ‘ƐŝůĞŶƚůǇƐŝůĞŶĐĞ ?ŽďũĞĐƚŝŽŶƐƚŽƚŚĞstatus quo ďǇ ‘ĂďƐŽƌƉƚŝŽŶ ? ?appearing to agree with a 
challenge while taking little action to resolve it. When challenged in Parliament, the minister claimed 
 ‘ŝƚŝƐƐŝŵƉůǇŶŽƚƚƌƵĞƚŚĂƚǁĞŚĂǀĞŶŽƚƚĂŬĞŶŽŶďŽĂƌĚĂůůƚŚĞƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐ ?ŽĨƚŚĞD
(Newton, 2017). But by not actually implementing these recommendations, ministers sustain 
conditions that are harmful for other people. In the section below, I examine the ways in which 
political actors represented themselves and these other people in their discourse. 
 
 ǮBeing huǯǣ  
 
The critical realist approach sees discourses as sets of statement that construct objects, which are  
deployed by social actors who have reasons for constructing such objects in that way. Their uses of 
these discourses goes on to influence the cultural context in which future discourses are created and 
ĚĞƉůŽǇĞĚ ?ĂƐƉĂƌƚŽĨƚŚĞ ‘ŵŽƌƉŚŽŐĞŶĞƚŝĐ ?development of social action (Archer, 2000). We can trace 
various forms of agency in the textual data gathered for this analysis. We can see, for example, a 
ĨŽƌŵŽĨ ‘ĐŽƌƉŽƌĂƚĞĂŐĞŶĐǇ ?(Archer, 2000) at play in the presentation of the government as the co-
ŽƌĚŝŶĂƚŽƌŽĨĂƌĂŶŐĞŽĨ ‘ƉĂƌƚŶĞƌƐ ?ŝŶƚŚĞĂƚƚĞŵƉƚƚŽƌĞĚƵĐĞĚƌƵŐƵƐĞ ? 
 
This form of agency is clearly stated in ministerial communications in the dataset, especially in the 
blog written by the Home Secretary to introduce the drug strategy (Rudd, 2017). She constructs 
ŚĞƌƐĞůĨĂƐĂƉŽǁĞƌĨƵůĂŶĚďĞŶĞǀŽůĞŶƚĂŐĞŶƚ P ‘DǇũŽďĂƐ,ŽŵĞ^ĞĐƌĞƚĂƌǇŝƐƚŽŬĞĞƉĨĂŵŝůŝĞƐĂŶĚ
communities across our country ƐĂĨĞ ? ?^ŚĞƐƚĂƚĞƐŚŽǁƐŚĞǁŝůůůĞĂĚŽƚŚĞƌorganisations in achieving 
ƚŚŝƐƚĂƐŬƚŚƌŽƵŐŚĂ ‘ƌƵŐ^ƚƌĂƚĞŐǇŽĂƌĚƚŚĂƚ/ǁŝůůƉĞƌƐŽŶĂůůǇĐŚĂŝƌƚŽĞŶƐƵƌĞĞǀĞƌǇŽŶĞŝƐ
ĂĐĐŽƵŶƚĂďůĞ ? ?ŶĚƐŚĞĐůĞĂƌůǇƐƚĂƚĞƐƚŚĞƵůƚŝŵĂƚĞĂŝŵŽĨƚŚĞĐŽůůĂďŽƌĂƚŝǀĞĞĨĨŽƌƚƚŚĂƚƐŚĞǁŝůů lead: 
 ‘tĞŽǁĞŝƚƚŽĨƵƚƵƌĞŐĞŶĞƌĂƚŝŽŶƐƚŽǁŽƌŬƚŽŐĞƚŚĞƌĨŽƌĂƐŽĐŝĞƚǇĨƌĞĞŽĨĚƌƵŐƐ ? ? In other words, a 
society in which there are no people who use drugs. 
 
The 2017 drug strategy and ministerial speech are also full of references to how the government will 
lead a collaborative, multi-partner approach that will, through the enacted agency of the 
ŐŽǀĞƌŶŵĞŶƚ ?ƌĞĚƵĐĞĚƌƵŐƵƐĞĂŶĚƉƌŽƚĞĐƚĐŽŵŵƵŶŝƚŝĞƐĂŶĚ ‘ƚŚĞǀƵůŶĞƌĂďůĞ ? ?/ŶĚĞƉůŽǇŝŶŐƚŚŝƐ
discourse, government ministers construct themselves as the central players in the dramatic struggle 




Remarkably absent from this constructed drama are the people whom it most directly concerns; i.e. 
people who use drugs. Drug use is never presented as an active choice, taken by responsible adults. 
People who use drugs are constructed not as agents in their own right, but as objects of the 
ŐŽǀĞƌŶŵĞŶƚ ?ƐĂĐƚŝŽŶƐŝŶƉƌŽƚĞĐƚŝŶŐƚŚĞŵ ?
 
The trope which ministers repeatedly use is to describe the objects of their policies as  ‘ǀƵůŶĞƌĂďůĞ ? ?
The concept of vulnerability appears over 20 times in the drug strategy document and is central to it 
(Wincup & Brown, 2018). Indeed, the job title of the junior minister responsible for drugs policy does 
not include the ǁŽƌĚĚƌƵŐƐ ?^ŚĞŝƐƚŚĞ ‘Parliamentary Under Secretary of State for Crime, 
^ĂĨĞŐƵĂƌĚŝŶŐĂŶĚsƵůŶĞƌĂďŝůŝƚǇ ? ?ĞƐĐƌŝďŝŶŐƉĞŽƉůĞŵĞƌĞůǇĂƐ ‘ǀƵůŶĞƌĂďůĞ ?ĚĞŶŝĞƐƚŚĞŝƌĂŐĞŶĐǇ ?/ƚ
justifies the taking of decisions by others on their behalf. As Brown (2017) has noted, the status of 
being vulnerable is conferred on groups who are seen as passive victims of circumstance. But this 
only leads to governmental responsibility to act if they conform with attempts to protect them. 
Social exclusion has intensified for people who do not comply (Grover, 2010; Young, 1999). 
 
DŝŶŝƐƚĞƌƐ ?description of the objects of drug policy as a generic ĂĚũĞĐƚŝǀĞ ? ‘ƚŚĞǀƵůŶĞƌĂďůĞ ? ?ĂǀŽŝĚƐ
having to give these people a name, or describe their most pertinent social characteristics.2 Age is 
mentioned in the dataset, usually either in the context of protecting young people, or as an 
ĞǆƉůĂŶĂƚŝŽŶĨŽƌŝŶĐƌĞĂƐŝŶŐĚĞĂƚŚƐĂŵŽŶŐĂŶ ‘older ĐŽŚŽƌƚ ?ŽĨƉĞŽƉůĞǁŚŽƵƐĞŚĞƌŽŝŶ ?KƚŚĞƌƐŽĐŝĂů
characteristics, such as race, gender and class are hardly mentioned. Gender, for example, is only 
ŵĞŶƚŝŽŶĞĚŝŶƌĞůĂƚŝŽŶƚŽƚŚĞ ‘ǀƵůŶĞƌĂďŝůŝƚǇ ?ŽĨĨĞŵĂůĞƐĞǆǁŽƌŬĞƌƐ(Wincup & Brown, 2018).  
 
The social distribution of drug-related death was highlighted in the ACMD (2016a) report, but not in 
the 2017 drug strategy. In this way, the people who suffer most from drug-related deaths have been 
rendered invisible by governmental discourse. They are simultaneously hidden amongst the other 
groups considered vulnerable, and stigmatised as passive, unemployable scroungers (Wincup & 
Monaghan, 2016). This is entirely coŶƐŝƐƚĞŶƚǁŝƚŚƌĐŚĞƌ ?Ɛ ? ? ? ? ? ?ƐƵŐŐĞƐƚŝŽŶƚŚĂƚŐƌŽƵƉƐǁŚŽůĂĐŬ
structural power will find it difficult to articulate their concerns and get them culturally recognised.  
 
This lack of articulation has two forms. One is the lack of voice. The other is the lack of collective 
mobilisation. People without corporate agency find it difficult to create a platform from which to 
communicate their shared problems. As Sayer (2005, p. 158) ƉƵƚƐŝƚ ? ? ?ƚ ?ŚĞƉŽŽƌĞƐƚĂƌĞ ?ŶŽƚŽŶůǇ
materially deprived but linguistically disappropriated and hence disempowered'. People without 
voice also find it difficult to link their interests with those of other groups in order to create shared 
goals and strategic action. They therefore cannot attain the status of corporate agency. They are left 
with their status as Ă ‘ƉƌŝŵĂƌǇĂŐĞŶƚ ?. This is a term that Archer uses to describe collectivities which 
have not recognised a common interest and developed a set of common goals which they can strive 
for collectively.  
                                                          
2 A minister only mentioned one person who died by name (Newton, 2017). This was an exceptional case of a 
15 year old girl called Martha whose death was related to MDMA. She was remembered during a debate on 
drug policy by two Labour MPs (Jeff Smith and Louise Haigh) and a Liberal Democrat (Layla Moran). Her 
mother (Anne-Marie Cockburn) was in the public gallery of the House of Commons for the debate. In general, 





In the data analysed for this article, ministers accord to themselves the qualities of fully human and 
moral agents. They present themselves as acting to safeguard society from an external evil which 
threatens it. In doing so, they deny to people who suffer most from drug problems the status of 




While the people most affected by drug-related deaths do not have corporate agency in policy 
discussions, mĞŵďĞƌƐŽĨƚŚĞƉƵďůŝĐŚĞĂůƚŚ ‘ƉŽůŝĐǇĐŽŶƐƚĞůůĂƚŝŽŶ ?(Stevens & Zampini, 2018) do have 
some articulated agency. These health professionals, academics and non-governmental 
organisations work alongside each other in arguing for policy change, as exemplified in reports from 
the ACMD, as well as the UK Drug Policy Commission (UKDPC, 2012), the Royal Society of Arts (RSA 
Commission on Illegal Drugs Communities and Public Policy, 2007), the British Medical Association 
(BMA Board of Science, 2013) and both the Royal Society and the Faculty of Public Health (Royal 
Society of Public Health, 2016), followed by the Royal College of Physicians (2018). They are 
institutionally committed to arguing for  ‘ĞǀŝĚĞŶĐĞ-ďĂƐĞĚ ?policy change (Lancaster, 2016; Smith, 
2007). But their (and my) deployment of research evidence in policy debates on drug-related deaths 
has not had the intended effect of changing policy. 
 
In the data analysis, I observed that when politicians argue for policy change on the basis of 
evidence, they were most powerfully met with moral claims, rather than evidential refutation. I 
ĚĞƐĐƌŝďĞƚŚŝƐĂƐĂ ‘ŵŽƌĂůƐŝĚĞƐƚĞƉ ? ?dŚŝƐŽĐĐƵƌƐǁŚĞŶĂƉŽůŝƚŝĐĂůĂĐƚŽƌĂǀŽŝĚƐŵĂŬŝŶŐĐŚĂŶŐĞƐŽŶƚŚĞ
basis of evidence by citing the important of moral concerns. In the data collected for this article, it is 
most clearly visible in the response given by Theresa May to a Parliamentary question on 20th 
December 2017.  The Scottish Nationalist MP, Ronnie Cowan, referred to the rise in deaths and to 
ĞǀŝĚĞŶĐĞĨƌŽŵ ‘ĞŝŐŚƚƵƌŽƉĞĂŶĐŽƵŶƚƌŝĞƐ ?ƉůƵƐƵƐƚƌĂůŝĂĂŶĚĂŶĂĚĂ ?ŽŶƚŚĞĞĨĨĞĐƚŝǀĞŶĞƐƐŽĨ
 ‘ƐƵƉĞƌǀŝƐĞĚĚƌƵŐĐŽŶƐƵŵƉƚŝŽŶƌŽŽŵƐ ? ?,ĞƚŚĞŶĂƐŬĞĚ ? ‘ŝŶƚŚĞŝŶƚĞƌĞƐƚƐŽĨƉƵďůŝĐŚĞĂůƚŚ ?ǁŝůůƚŚĞ
WƌŝŵĞDŝŶŝƐƚĞƌŝŶƚƌŽĚƵĐĞZƐŝŶƚŚĞhŶŝƚĞĚ<ŝŶŐĚŽŵ ? ?,ĞƌƌĞƉůǇǁĂƐŚŝŐŚůǇŝŶĨŽƌŵĂƚŝǀĞ P 
I have a different opinion to some Members of this House. Some are very liberal in their 
approach to the way that drugs should be treated. I am very clear that we should recognise 
ƚŚĞĚĂŵĂŐĞƚŚĂƚĚƌƵŐƐĚŽƚŽƉĞŽƉůĞ ?ƐůŝǀĞƐ ?KƵƌĂŝŵƐŚŽƵůĚďĞƚŽĞŶƐƵƌĞƚŚĂƚƉĞŽƉůĞĐŽŵĞ
off drugs, do not go on drugs in the first place and keep clear of drugs. That is what we 
should focus on (May, 2017a). 
 
/ŶƚŚŝƐƌĞƉůǇ ?DĂǇĚƌĂǁƐĂĐůĞĂƌ ‘ŵŽƌĂůďŽƵŶĚĂƌǇ ? (Lamont, 1992; Sayer, 2005) between herself and 
 ‘ƐŽŵĞDĞŵďĞƌƐŽĨƚŚŝƐ,ŽƵƐĞ ? ?^ŚĞĚĞƐĐƌŝďĞĚƚŚĞŵĂƐ ‘ǀĞƌǇůŝďĞƌĂů ? ?ƚŚĞƌĞďǇĐŽŶŶŽƚŝŶŐŚĞƌƐĞůĨĂƐƚŚĞ
ŽƉƉŽƐŝƚĞŽĨůŝďĞƌĂůůǇŝŶĚƵůŐĞŶƚ ?ĐŽŶƐĞƌǀĂƚŝǀĞĂŶĚƚŽƵŐŚ ?^ŚĞĚŽĞƐŶŽƚĂƚƚĞŵƉƚƚŽĐŚĂůůĞŶŐĞŽǁĂŶ ?Ɛ
ĐůĂŝŵƐŽŶƚŚĞĞĨĨĞĐƚŝǀĞŶĞƐƐŽĨZƐ ?/ŶƐƚĞĂĚƐŚĞƌĞƉĞĂƚƐŚĞƌŐŽǀĞƌŶŵĞŶƚ ?ƐƉŽƐŝƚŝŽŶŽŶƚŚĞŶĞĞĚƚŽ
rid ƐŽĐŝĞƚǇŽĨĚƌƵŐƐ ?dŚĞŐŽǀĞƌŶŵĞŶƚ ?ƐĚƌƵŐƐƚƌĂƚĞŐǇĞǀĂůƵĂƚŝŽŶƐŚŽǁƐƚŚĂƚƚŚĞŐŽǀĞƌŶŵĞŶƚĚŽĞƐŶŽƚ
have the evidence to tell it how this aim could be achieved. It is a moral aspiration, not an evidenced 
position.  
 
Here, May was repeating the moral sidestep she had already practised on the 22nd November 2017. 
When challenged by Crispin Blunt (a Conservative MP) ŽŶƚŚĞ ‘ůĞŐĂůŝƐĂƚŝŽŶĂŶĚƌĞŐƵůĂƚŝŽŶŽĨ
10 
 
ĐĂŶŶĂďŝƐŵĂƌŬĞƚƐ ?ŝŶƚŚĞh^ĂŶĚĂŶĂĚĂĂŶĚ ‘ĚĞĐƌŝŵŝŶĂůŝƐĂƚŝŽŶŝWŽƌƚƵŐĂůĂŶĚĞůƐĞǁŚĞƌĞ ? ?Ɛhe 
said: 
When I was Home Secretary, work was undertaken by the Home Office on the experience in 
a number of countries and the different ways they approached the issue of drugs, but I am 
afraid that I have a different opinion from my honourable Friend ŽŶĚƌƵŐƐ ?It is right that 
we continue to fight the war against drugs (May, 2017b). 
 
Note again the absence of discussion or refutation of evidence. May mentions research by the Home 
Office ŽŶƚŚĞĞǆƉĞƌŝĞŶĐĞ ‘ŝŶĂŶƵŵďĞƌŽĨŽƚŚĞƌĐŽƵŶƚƌŝĞƐ ? ?ďƵƚƐŚĞĚŽĞƐŶŽƚƵƐĞŝƚƐĨŝŶĚŝŶŐƐ ?Rather, 
she almost disowns it by stating that it  ‘ǁĂƐƵŶĚĞƌƚĂŬĞŶ ?ŝŶƚŚĞƉĂƐƐŝǀĞvoice. The report in question 
showed there is little cross-national relationship between the severity of penal sanctions for drug 
offences and levels of drug use and related harms (Home Office, 2014). Then ministerial colleagues, 
Norman Baker and Nick Clegg (both Liberal Democrats) have since reported that May ordered 
changes to the report, removing recommendations to consider following the Portuguese example 
(Asthana, 2016; BBC, 2014). In her Parliamentary response to Mr Blunt, she refers not to the 
evidence contained in the report, but to a moral crusade;  ‘ƚŚĞǁĂƌ ĂŐĂŝŶƐƚĚƌƵŐƐ ? ?
 
This sidestep away from refuting claims on the basis of evidence is visible in several ministerial 
statements in the data collected for this article. It is interesting in what it reveals about how 
ministers deal with pressure that emanates from the public health policy constellation. It is also 
interesting to note the moral content to which this sidestep is taken, as drug policy is often decided 
on moral rather than evidential grounds (Zampini, 2018). The sidestep does not move to a morality 
of care or compassion, but rather to abstinent purity and conformity. These are quintessentially 
ĐŽŶƐĞƌǀĂƚŝǀĞ ‘ŵŽƌĂůĨŽƵŶĚĂƚŝŽŶƐ ?(Graham, Haidt, & Nosek, 2009) which enable their proponents to 
ƉĞƌĨŽƌŵ ‘ƚŽƚĞŵŝĐƚŽƵŐŚŶĞƐƐ ?(Stevens, 2011b); the willingness to show hostility to a supposedly 





TŚŝƐŝƐĂŶ ‘ŝŶƚĞŶƐŝǀĞ ?ƐƚƵĚǇƚŚĂƚŝƐƉƌŝŵĂƌŝůǇĐŽŶĐĞƌŶĞĚǁŝƚŚ ‘ǁŚĂƚŵĂŬĞƐƚŚŝŶŐƐŚĂƉƉĞŶ ?ŝŶĂƐƉĞĐŝĨŝĐ
case (Sayer, 2000, p. 20). Here, the focus is on UK drug policy on opioid-related death between 2016 
ĂŶĚ ? ? ? ? ?DŽƌĞ ‘ĞǆƚĞŶƐŝǀĞ ?ƌĞƐĞĂƌĐŚĐŽƵůĚinclude comparisons with other periods and topics in UK 
drug policy, or the response to drug-related deaths in other countries. The USA, Canada and France 
would be particularly interesting and contrasting cases, given their different trajectories in policy 
and death rates.  
 
Some hints on the differences between this and other periods in UK drug policy are given by the 
greater willingness of previous governments to invest in life-saving services for people who use 
drugs (MacGregor, 2017). Indeed, a previous Conservative minister gave the following response 
when challenged to implement ACMD advice on reducing a health problem that was seen as a threat 
to the whole of society, rather than just to people who use heroin:  ‘when a legitimate basis for 
expenditure is found our task is to find the resources to meet it. I see the AIDS budget as one which 




Nowhere in recent debates has a minister promised that as the scale of drug-related deaths 
increases, so should the budget for reducing them. To do so would contradict the fundamental 
political economic project of the currently dominant corporate agent; shrinking public expenditure 
in ways that protect the wealthy and so ƉƌŽĚƵĐĞĂ ‘ĚŝǀŝƐŝǀĞǁĞůĨĂƌĞƐƚĂƚĞ ?(Taylor-Gooby, 2016). This 
is a form of social provision which differs markedly from the liberal welfare state that was created 
during the post-war, post-Beveridge report consensus by both Conservative and Labour parties, 
which Joseph (1976) so vehemently decried.  
 
Instead of acting as an expression of solidarity, the welfare system (and drug policy) now operate as 
a motor of division, channelling resentment towards working class people who are considered 
unwilling rather than unable to work. Such resentment can lead to support for punitive and 
stigmatising arrangements for the delivery of welfare as well as harsh penal sanctions in the criminal 
justice system (Grover, 2010; Young, 1999). It can also, as shown in this article, lead to a failure to 
provide effective services to save the lives of denigrated social groups, such as working class people 
who use heroin. /ŶƵƚůĞƌ ?Ɛ(2016) ƚĞƌŵƐ ?ƚŚĞƐĞůŝǀĞƐĂƌĞŶŽƚĐŽŶƐŝĚĞƌĞĚ ‘ŐƌŝĞǀĂďůĞ ?. Governmental 
ĚŝƐĐŽƵƌƐĞŽƉĞƌĂƚĞƐĂƐ ‘ĂŶŝŶƚƌŝŶƐŝĐĂůůǇƉŽůŝƚŝĐĂůŬŶŽǁůĞĚŐĞ-making processes that frame some lives as 
ŶŽƚǀŝƐŝďůǇŽƌƉĞƌĐĞƉƚŝďůǇƌĞĂůĂŶĚƚŚĞƌĞĨŽƌĞŶŽƚ “ůŽƐĞ-ĂďůĞ ? ?(Fraser, Farrugia, & Dwyer, 2018, p. 30). 
So effective measures to prevent these lives being lost and grieved are not taken. 
 
In public attitudes, however, there is ambivalence towards people who have problems with drugs. 
They are seen as deserving of both care and sanction (Matheson et al., 2014; Singleton, 2010). Some 
political actors have exploited this ambivalence to deepen the increasing fissiparousness that Archer 
observes in ĞĐŽŶŽŵŝĐĂůůǇ ‘ƌĞƐŝĚƵĂů ?groups who are excluded from power ŝŶ ‘ůĂƚĞǁĞůĨĂƌĞĐĂƉŝƚĂůŝƐŵ ?.
 ‘dŚĞŝƌsocial exclusion plus their diversity condemns them as a collectivity to the passivity of primary 
[rather than corporate] aŐĞŶĐǇ ? (Archer, 2000, p. 284). Resentment and vindictiveness against some 
sections of the working class has been used to win support (or at least acquiescence) for welfare 
reform and cuts to incomes and services (Grover, 2010), including to drug treatment budgets.   
 
ƌĐŚĞƌ ?ƐĐŽŶĐĞƉƚƐǀĂůƵĂďůǇŝŶĚŝĐĂƚĞƚŚĂƚƚŚŝƐŝƐŶŽƚũƵƐƚĂƚĂĐƚŝĐŽĨŽŶĞƉŽůŝƚŝĐĂůƉĂƌƚǇ ?ŝƚŝƐĂƐƚƌĂƚĞŐǇ
adopted by a social group who share interests and are structurally empowered to institutionalise 
their  ‘ƐĞůĨ-ŽƌŝĞŶƚĞĚƉĂƚƚĞƌŶƐŽĨƐŽĐŝĂůĐŽŐŶŝƚŝŽŶ ? (Piff & Robinson, 2017). This is visible in recent 
Conservative Party policy (Grimshaw & Rubery, 2012), but it was also present in the discourse of the 
 ‘EĞǁLabour ?ŐŽǀĞƌŶŵĞŶƚ ? ? ? ? ? W 2010). This government also changed welfare policy to emphasise 
individual responsibility and the morally authoritarŝĂŶ ‘ŽƚŚĞƌŝŶŐ ?ŽĨƵŶĚĞƐĞƌǀŝŶŐĐůĂŝŵĂŶƚƐ(Connor, 
2007). Civil servants, special advisers and Labour ministers created the  ‘ŚŝŐŚŚĂƌŵĐĂƵƐŝŶŐƵƐĞƌƐ ?
(PMSU, 2003) of crack and heroin as an object to be blamed for large portions of crime and targeted 
for control (MacGregor, 2017; Stevens, 2011a). This shows that corporate agency goes beyond the 
boundaries of political parties. A structurally advantaged social group can dominate the cultural, 
intellectual landscape (Archer, 2000). And this can feed into the policies of all parties for decades 
(Beland, 2005).  
 
ThĞĨŽĐƵƐŝŶŐŽĨďůĂŵĞŽŶ ‘ǁĞůĨĂƌĞƐĐƌŽƵŶŐĞƌƐ ?ĂŶĚ ‘ŚŝŐŚŚĂƌŵĐĂƵƐŝŶŐƵƐĞƌƐ ?contributed to the 
casting of people who use drugs as abject;  ‘ďĞŝŶŐǀŝůĞŽƌƵŶǁŽƌƚŚǇ ?ƌĞĨƵƐĞ ?ƐĐƵŵ ?ĚƌĞŐƐ ?humiliation, 
ĚĞŐƌĂĚĂƚŝŽŶ ?ĚŝƐƉŝƌŝƚĞĚŶĞƐƐ ?ĚĞƐƉŽŶĚĞŶĐǇ ?(Oxford English Dictionary, cited in Tyler, 2013, p. 20). As 




ŝŶĚŝǀŝĚƵĂůƐ ?(Tyler, 2013, p. 26).  
 
The discursive construction of people who use drugs as denigrated objects of fear and control during 
the New Labour era fed forward (morphogenetically) into Conservative ŵŝŶŝƐƚĞƌƐ ?non-performative 
ignoring of the social characteristics, agency and suffering of these people. These discursive practices 
have real consequences. The extra-discursive effects of class contempt against people who use 
heroin include the continuation of the project of partial state shrinkage, as well as the failure to 
implement evidence to reduce their deaths. 
Conclusion 
 
In the data analysed here, Conservative ministers displayed a high degree of corporate agency. They 
have acted and spoken consistently in support of the aim (which they share with their financial 
backers) to shrink state spending in ways that maintain the incomes and power ŽĨƚŚĞƌŝĐŚ ?ƌĐŚĞƌ ?Ɛ
concept of corporate agency as involving coordinated action towards shared goals fits these actions 
ǁĞůů ?,ĞƌĐŽŶĐĞƉƚŽĨ ‘residual ƉƌŝŵĂƌǇĂŐĞŶĐǇ ?ĂůƐŽŚĞůƉƐƵƐƚŽƵŶĚĞƌƐƚĂŶĚǁŚǇƉĞŽƉle who are 
potential agents in this debate have not been able to enact such agency, due to their difficulties in 
achieving either aspect of articulation. Working class people who use heroin do not have a platform 
from which to give voice to their concerns, and they have not created coordinated action in defence 
of their own interests.  
 
Members of the public health policy constellation have more presence in the debate. But their calls 
ƚŽĐŚĂŶŐĞƉŽůŝĐǇŚĂǀĞďĞĞŶĂǀŽŝĚĞĚƚŚƌŽƵŐŚŵŝŶŝƐƚĞƌƐƚĂŬŝŶŐĂ ‘ŵŽƌĂůƐŝĚĞƐƚĞƉ ?ĂǁĂǇĨƌŽŵƚŚĞ
evidence towards normative claims. Some researchers may be reluctance to act as campaigners as 
well as experts (Smith & Stewart, 2017). They may have a justifiable reluctance to take on the task of 
arbitrating on moral positions, as well as on the research evidence (Humphreys & Piot, 2012). But we 
should recognise that our recommendations are inherently value-laden (Zampini, 2018). 
Recommendations to reduce drug-related deaths typically prioritise compassion and the right to life 
over thĞĚĞƐŝƌĞĨŽƌĂ ‘ƐŽĐŝĞƚǇĨƌĞĞŽĨĚƌƵŐƐ ? ?
 
In future, we might see more political mobilisation both by people who use drugs and by members 
ŽĨƚŚĞƉƵďůŝĐŚĞĂůƚŚƉŽůŝĐǇĐŽŶƐƚĞůůĂƚŝŽŶ ?dŚŝƐĐŽƵůĚƉŽƐƐŝďůǇƚƵƌŶƉƵďůŝĐĂŵďŝǀĂůĞŶĐĞƚŽǁĂƌĚƐ ‘ƚŚĞ
ǀƵůŶĞƌĂďůĞ ?ŝŶƚŽƐƵpport for policies based on compassion and research evidence, rather than the 
moral positions of purity and conformity. In the meanwhile, the corporate agent which is currently in 
control of UK drug policy evidently fails to recognise the full humanity of the people most likely to 
die. So it refuses to compromise its moral and material preferences in order to implement measures 
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